Abstract
Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices.
Highlights
Cancer is a genetically and clinically diverse disease, with a tremendous amount of genetic heterogeneity across various malignant tumor types, invading and destroying nearby parts of the normal tissues [1]
The results indicated that Extracellular matrix metalloproteinase inducer (EMMPRIN) overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% confidence interval (CI): 2.212.75, P
Stratified based on the clinical stage, the results showed a significant association between EMMPRIN expression and the risk of clinical stage III+IV than stage I +II (OR=1.96, 95% CI:1.69-2.27, P
Summary
Cancer is a genetically and clinically diverse disease, with a tremendous amount of genetic heterogeneity across various malignant tumor types, invading and destroying nearby parts of the normal tissues [1]. Extracellular matrix metalloproteinase inducer (EMMPRIN, basigin, HAb18G, known as CD147) is a type I transmembrane glycoprotein of the immunoglobulin superfamily with two immunoglobulin-like domains [5, 6]. An increasing number of studies have demonstrated that EMMPRIN is associated with tumor growth, invasion and angiogenesis in www.impactjournals.com/oncotarget many malignant cancer, such as breast carcinoma [9], hepatocellular carcinoma [10] and prostate cancer [11], by regulating the expression of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) [12]. Some research data indicated that expression of EMMPRIN was obviously higher in tumor tissues than adjacent normal tissues, indicating that EMMPRIN might be useful for the prediction of prognosis in cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
